Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation

Abstract

Background:

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has been used as a bridge to cardiac recovery in patients following a major cardiac event. There is a lack of literature surrounding prolonged use of eptifibatide and optimal dosing during ECMO. This case report describes our experience with extended durations and standard dosing of eptifibatide in the setting of ECMO.

Case:

A 40-year-old male with a history of Marfan’s syndrome, aortic root and ascending aortic aneurysm status post a modified Bentall with a St. Jude mechanical aortic valve conduit and hemi-Cabrol with a Dacron graft to the left main coronary artery presented with exertional chest pain and was found to have an anastomotic narrowing to the left main which occluded while awaiting surgical revision. A rescue percutaneous coronary intervention at the anastomotic site was performed. Due to hemodynamic instability, he was placed on femoral VA-ECMO. The patient was started on anticoagulation for the ECMO circuit and eptifibatide to maintain stent patency. The patient experienced several bleeding episodes for which he received supportive care, endoscopic intervention and left gastric artery embolization. Eptifibatide was maintained at standard dosing and the heparin infusion was withheld. A coronary angiogram revealed no thrombus within the Cabrol graft a patent stent previously placed at the site of the distal graft-coronary anastomosis. The patient was decannulated from ECMO and underwent coronary artery bypass grafting and division of the hemi-Cabrol graft.

Conclusion:

While eptifibatide was effective in maintaining stent patency, our patient experienced several bleeding episodes during ECMO. Thus, the risks and benefits of concurrent antiplatelet and anticoagulant therapy must be appropriately weighed in this patient population. Additionally, as the need for dual antiplatelet therapy due to coronary stent implantation is increasing, further studies are needed to validate optimal dosing of eptifibatide in patients at a high risk of bleeding during ECMO.

Keywords

cardiac surgery extracorporeal membrane oxygenation bleeding eptifibatide drug eluting stent

Get full access to this article

View all access options for this article.

References

Zangrillo

Landoni

Biondi-Zoccai

et al . A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc 2013; 15: 172–178.

Cheng

Hachamovitch

Kittleson

et al . Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg 2014; 97: 610–616.

Aubron

Cheng

Pilcher

et al . Factors associated with outcomes of patients on extracorporeal support: a 5-year cohort study. Critical Care 2013, 17: R73.

Tauber

Streif

Fritz

et al . Predicting transfusion requirements during extracorporeal membrane oxygenation. J Cardiothoraic Vasc Anesth 2016; 30: 692–701.

Oliver

. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13: 154–175.

Muntean

. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artificial Organs 1999; 23: 979–983.

Esper

Levy

Waters

Welsby

. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg 2014; 118: 731–743.

Eptifibatide [package insert]. https://www.merck.com/product/usa/pi_circulars/i/integrilin/integrilin_pi.pdf. Accessed: November 2017.

Zeymer

Wienbergen

. A review of clinical trials with eptifibatide in cardiology. Cardiovascular Drug Reviews 2007; 25: 301–315.

10.

Hoskins

Kacharava

Green

Mavromatis

. Percutaneous intervention of Cabrol graft-left main anastomosis during acute myocardial infarction. Int J Cardiol. 2010; 140: e27–e29.

11.

Jang

Jeong

Ahn

et al . A successful primary percutaneous coronary intervention twelve days after a Cabrol composite graft operation in Marfan Syndrome. Korean Circ J 2010; 40: 247–250.

12.

Shridhar

Smith

Khalil

Lasorda

Chun

. A unique case of successful mechanical thrombectomy and stenting of Cabrol graft: a case report. WJCD 2016; 6: 295–299.

13.

Tsai

Wei

Hsieh

Chang

. Salvage of left Cabrol limb occlusion by minimally invasive direct coronary bypass grafting. Interact Cardiovasc Thorac Surg 2004; 3: 678–681.

14.

Staudacher

Biever

Benk

Ahrens

Bode

Wengenmayer

. Dual antiplatelet therapy (DAPT) versus no antiplatelet therapy and incidence of major bleeding in patients on venoarterial extracorporeal membrane oxygenation. PLoS ONE 2016; 11: e0159973.

15.

He H

Zhou

Long

et al . Using anti-platelet therapy to prevent extracorporeal membrane oxygenator thrombosis without heparin resistance and with thrombocytopenia. Critical Care 2014, 18: 595.

16.

Shekar

Fraser

Smith

Roberts

. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012; 27: 741.e9–e18.

17.

Shekar

Roberts

Mcdonald

et al . Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care 2015; 19: 164.